You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 14, 2025

FOLLISTIM Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: FOLLISTIM
Recent Clinical Trials for FOLLISTIM

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Ferring PharmaceuticalsPhase 2
Center for Human ReproductionPhase 1/Phase 2
Michigan Reproductive MedicinePhase 4

See all FOLLISTIM clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for FOLLISTIM Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for FOLLISTIM Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. FOLLISTIM AQ follitropin beta Injection 021273 5,929,028 2018-04-14 Company disclosures
Organon Usa Llc, A Subsidiary Of Organon & Co. FOLLISTIM AQ CARTRIDGE follitropin beta Injection 021211 5,767,251 2013-01-22 Company disclosures
Organon Usa Llc, A Subsidiary Of Organon & Co. FOLLISTIM AQ CARTRIDGE follitropin beta Injection 021211 5,929,028 2018-04-14 Company disclosures
Organon Usa Llc, A Subsidiary Of Organon & Co. FOLLISTIM AQ CARTRIDGE follitropin beta Injection 021211 7,446,090 2026-07-07 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for FOLLISTIM Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for FOLLISTIM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C201000010 Spain ⤷  Try for Free PRODUCT NAME: CORIFOLITROPINA ALFA; NATIONAL AUTHORISATION NUMBER: EU/1/09/609/001-002; DATE OF AUTHORISATION: 20100125; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/09/609/001-002; DATE OF FIRST AUTHORISATION IN EEA: 20100125
6/2010 Austria ⤷  Try for Free PRODUCT NAME: CORIFOLLITROPIN ALFA; REGISTRATION NO/DATE: EU/1/09/609/001-002 20100125
132010901848521 Italy ⤷  Try for Free PRODUCT NAME: CORIFOLLITROPINA ALFA(ELONVA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/09/609/001-002, 20100125
91655 Luxembourg ⤷  Try for Free PRODUCT NAME: CORIFOLLITROPINE ALFA ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (ELONVA ); AUTHORISATION NUMBER AND DATE: EU/1/09/609/001-002 - ELONVA-CORIFOLLITROPINE ALFA; 20100125
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory for the Biologic Drug: FOLLISTIM

Last updated: July 4, 2025

Introduction

In the competitive landscape of biologic drugs, FOLLISTIM stands out as a key player in fertility treatments. This recombinant follicle-stimulating hormone (FSH), marketed by Organon (a spin-off from Merck), drives outcomes in in vitro fertilization (IVF) and other assisted reproductive technologies. As global infertility rates climb, FOLLISTIM's role in a multibillion-dollar market demands scrutiny. This analysis delves into its market dynamics and financial trajectory, offering insights for investors, pharmaceutical executives, and healthcare strategists navigating an era of patent expirations and biosimilar threats.

Overview of FOLLISTIM

FOLLISTIM, or follitropin beta, emerged in the late 1990s as a synthetic alternative to natural FSH, revolutionizing infertility care. Unlike traditional gonadotropins derived from urine, FOLLISTIM's production via recombinant DNA technology ensures purity and consistency, reducing risks like contamination. Organon received U.S. Food and Drug Administration (FDA) approval in 1997, positioning it as a cornerstone for ovulation induction and controlled ovarian hyperstimulation.

The drug's mechanism targets the hypothalamic-pituitary-ovarian axis, stimulating follicular development in women undergoing fertility treatments. Clinicians favor it for its predictable dosing and lower immunogenicity compared to older therapies. In 2023, FOLLISTIM generated approximately $500 million in global sales, underscoring its enduring demand amid rising IVF procedures worldwide [1].

Market analysts highlight FOLLISTIM's expansion into emerging economies, where improving healthcare infrastructure boosts access to advanced reproductive medicine. Yet, its biologic nature invites scrutiny over manufacturing complexities and regulatory hurdles, shaping its competitive edge.

Current Market Dynamics

The global fertility drugs market, valued at around $5.5 billion in 2023, is projected to grow at a compound annual growth rate (CAGR) of 8% through 2030, driven by factors like delayed parenthood and lifestyle-related infertility [2]. FOLLISTIM commands a significant share, particularly in North America and Europe, where it faces stiff competition from Merck's own Gonal-F and biosimilars like Bemfola from Finox Biotech.

Key growth drivers include the surge in IVF cycles—over 2.5 million performed globally in 2022—and increasing awareness of male infertility treatments [3]. Organon's strategic partnerships, such as collaborations with fertility clinics, have expanded FOLLISTIM's reach, especially in Asia-Pacific regions like China and India. Here, regulatory reforms are easing drug approvals, potentially doubling market penetration by 2028.

However, challenges abound. Biosimilars, entering the market post-patent expiration in 2015, have eroded FOLLISTIM's pricing power. In the U.S., competitors like Sandoz's biosimilar offerings have captured 15-20% of the FSH segment, compelling Organon to slash prices by up to 10% in recent years [4]. Supply chain disruptions, exacerbated by the COVID-19 pandemic, further strained distribution, highlighting vulnerabilities in biologic manufacturing.

Regulatory dynamics also play a pivotal role. The FDA's stringent biosimilar approval pathway, outlined in the Biologics Price Competition and Innovation Act, fosters competition while ensuring safety. For FOLLISTIM, this means ongoing post-market surveillance to maintain its label, even as Organon invests in next-generation formulations to differentiate the product.

Patent Landscape and Regulatory Environment

FOLLISTIM's intellectual property framework has evolved significantly since its inception. The original composition-of-matter patent, granted in the 1990s, expired in 2015 in major markets, opening the door to biosimilars [5]. Organon responded with secondary patents on delivery systems, such as the FOLLISTIM Pen, which extends exclusivity until 2027 in some regions.

This layered patent strategy exemplifies how biopharma companies defend market share. In Europe, the European Medicines Agency (EMA) upheld Organon's patents against challenges, granting a data exclusivity extension that delays full generic competition. Conversely, in emerging markets like Brazil, weaker patent enforcement has led to earlier biosimilar entries, compressing margins.

Regulatory milestones, including FDA re-approvals for new indications, keep FOLLISTIM relevant. For instance, a 2021 label expansion for polycystic ovary syndrome (PCOS) treatments broadened its application, potentially adding $100 million in annual revenue [6]. Yet, evolving guidelines on biosimilar interchangeability pose risks, as payers increasingly favor lower-cost alternatives.

Investors should monitor upcoming patent cliffs. With Organon's pipeline focusing on novel FSH analogs, any delays in clinical trials could jeopardize FOLLISTIM's financial stability, underscoring the need for diversified R&D investments.

Financial Performance and Trajectory

Organon's financials reflect FOLLISTIM's mixed trajectory. In 2023, the drug contributed roughly 15% to Organon's total revenue of $3.4 billion, with net sales reaching $520 million—a 5% year-over-year increase driven by volume growth in IVF procedures [7]. However, gross margins slipped to 65% from 68% in 2022, primarily due to biosimilar competition and rising manufacturing costs.

Quarterly earnings reports reveal resilience: Q2 2023 saw FOLLISTIM sales climb 7% in the U.S., buoyed by premium pricing in high-end fertility centers. Globally, emerging markets accounted for 30% of sales, with projections estimating a 10% CAGR through 2026 as demand in Asia surges [8]. Organon's acquisition by Schering-Plough in 2009 and subsequent Merck spin-off in 2021 have optimized cost structures, channeling profits into marketing and R&D.

Looking ahead, financial models forecast FOLLISTIM's revenue peaking at $600 million by 2025 before a potential 15% decline post-2027 patent expirations [9]. Mitigation strategies include premium pricing in untapped markets and bundling with Organon's other women's health products. Analysts at Bloomberg Intelligence predict that strategic alliances, like the recent partnership with Ferring Pharmaceuticals, could offset losses by expanding distribution networks.

Despite these positives, external factors like inflation and currency fluctuations threaten profitability. In 2023, a 5% hit from the euro's depreciation against the dollar impacted European sales, illustrating the drug's exposure to macroeconomic shifts.

Challenges and Opportunities

FOLLISTIM navigates a landscape riddled with obstacles, from biosimilar encroachment to ethical debates over fertility treatments. Competition intensifies as players like EMD Serono advance next-generation FSH therapies with longer half-lives, potentially reducing dosing frequency and patient burden.

Yet, opportunities abound. The aging population and rising infertility rates—estimated at 15% globally—fuel demand for reliable options like FOLLISTIM [10]. Organon's pivot to digital health, including app-based monitoring for IVF patients, enhances user engagement and differentiates the brand. Additionally, regulatory incentives for rare disease applications could unlock new revenue streams.

Sustainability emerges as a wildcard. With growing emphasis on eco-friendly manufacturing, Organon's efforts to reduce carbon emissions in FOLLISTIM production align with ESG investor preferences, potentially boosting stock valuations.

Future Outlook

As the fertility market matures, FOLLISTIM's trajectory hinges on innovation and adaptation. Organon's R&D investments, totaling $500 million in 2023, target biosimilar-resistant variants, with clinical trials slated for 2025 [11]. If successful, these could extend market dominance into the 2030s.

Stakeholders must prepare for volatility: Biosimilar approvals in key markets like Japan could erode 20% of sales by 2028, per industry forecasts. Conversely, personalized medicine trends—tailoring FSH doses via genetic testing—offer a pathway for premium positioning. For business professionals, monitoring Organon's earnings calls and patent filings will be crucial for informed decisions.

Key Takeaways

  • FOLLISTIM maintains strong demand in the growing fertility market, with 2023 sales nearing $520 million despite biosimilar pressures.
  • Patent expirations and regulatory shifts pose risks, but secondary protections and new indications provide short-term stability.
  • Financial projections indicate modest growth through 2025, followed by potential declines, emphasizing the need for strategic partnerships.
  • Opportunities in emerging markets and digital integration could counter challenges, driving long-term value.
  • Investors should weigh macroeconomic factors and competition when assessing FOLLISTIM's role in portfolios.

FAQs

  1. What factors are driving the growth of FOLLISTIM's market?
    The rise in IVF procedures and increasing infertility rates, particularly in urban areas, are key drivers, with global demand projected to grow at an 8% CAGR through 2030.

  2. How have biosimilars impacted FOLLISTIM's pricing?
    Biosimilars have forced price reductions of up to 10% in competitive markets, squeezing margins but also stimulating volume growth through broader accessibility.

  3. What is the current patent status of FOLLISTIM?
    The original patents expired in 2015, but secondary patents on delivery devices extend exclusivity in some regions until 2027, offering temporary protection.

  4. How does FOLLISTIM compare financially to competitors?
    FOLLISTIM outperforms rivals like Gonal-F in emerging markets due to strategic pricing, though overall margins lag behind due to biosimilar competition.

  5. What future developments could affect FOLLISTIM's trajectory?
    Advances in personalized FSH therapies and potential label expansions for new indications could enhance its market position, while further biosimilar entries may challenge revenues.

Sources

  1. Organon Annual Report 2023.
  2. Grand View Research, Fertility Drugs Market Report, 2023.
  3. International Committee Monitoring Assisted Reproductive Technologies, 2022 Data.
  4. Sandoz Press Release on Biosimilar Approvals, 2022.
  5. U.S. Patent and Trademark Office Database, FOLLISTIM Patents.
  6. FDA Label Expansion Announcement, 2021.
  7. Organon Q4 Earnings Report, 2023.
  8. Bloomberg Intelligence Forecast for Biologics, 2023.
  9. Statista Projections for Fertility Market, 2024.
  10. World Health Organization Infertility Statistics, 2023.
  11. Organon R&D Pipeline Update, 2023.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.